{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:40Z","timestamp":1790880700614,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ABP 654 is a biosimilar to ustekinumab reference product (RP). ABP 654 has been shown to have an amino acid sequence identical to ustekinumab RP and they are similar in structure, purity and potency, as well as clinical pharmacokinetics and safety in healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy, safety and immunogenicity of ABP 654 and ustekinumab RP in patients with moderate-to-severe plaque psoriasis in a randomized double-blinded active-controlled single-transition comparative clinical study (NCT04607980).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized 1 : 1 to receive ABP 654 or ustekinumab RP at a weight-based dose of 45\u2005mg or 90\u2005mg administered subcutaneously on day 1 (week 0), week 4 and week 16. At week 28, patients with a \u2265 75% improvement in Psoriasis Area and Severity Index (PASI) were re-randomized such that those initially randomized to ABP 654 continued to receive ABP 654 and those initially randomized to ustekinumab RP were re-randomized to either continue on ustekinumab RP or transition to ABP 654. The primary efficacy endpoint was percentage improvement in PASI from baseline to week 12. Secondary endpoints included additional efficacy measurements, as well as an assessment of adverse events and antidrug antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 12, the observed mean (SD) percentage improvement in PASI from baseline was 81.9 (19.9) and 81.9 (19.6) for the ABP 654 and ustekinumab RP treatment groups, respectively. The point estimate of the mean difference in percentage PASI improvement from baseline to week 12 between the treatment groups was 0.14 with a two-sided 90% confidence interval (CI) of (\u20132.6 to 2.9), well within the prespecified similarity margin of (\u201310 to 10). In addition, throughout the study, secondary efficacy analyses and safety and immunogenicity profiles were similar across the treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results indicate that ABP 654 and ustekinumab RP are clinically similar in efficacy, safety and immunogenicity in patients with moderate-to-severe plaque psoriasis. Further, a single transition from ustekinumab RP to ABP 654 at week 28 had no impact on the efficacy, safety or immunogenicity results for the remainder of the 52-week study, supporting a conclusion of no clinically meaningful differences between ABP 654 and ustekinumab RP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae402","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:25:28Z","timestamp":1729524328000},"page":"826-836","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a\u00a0randomized double-blinded active-controlled comparative clinical study over 52 weeks"],"prefix":"10.1093","volume":"192","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[{"name":"Oregon Medical Research Center , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials Probity Medical Research , Waterloo, ON ,","place":["Canada"]},{"name":"Department of Medicine, Division of Dermatology, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barragan","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chow","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel\u00a0T","family":"Mytych","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Dermatology Institute and Skin Care Center, Inc. Clinical Science Institute , Santa Monica, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Crowley","sequence":"additional","affiliation":[{"name":"Bakersfield Dermatology and Skin Cancer Medical Group , Bakersfield, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Franklin","sequence":"additional","affiliation":[{"name":"Amgen Inc. , Thousand Oaks, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2025042813573044400_ljae402-B1"},{"key":"2025042813573044400_ljae402-B2","author":"European Medicines Agency"},{"key":"2025042813573044400_ljae402-B3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjd.14267","article-title":"Biosimilars for psoriasis: preclinical analytical assessment to determine similarity","volume":"174","author":"Blauvelt","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025042813573044400_ljae402-B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjd.15067","article-title":"Biosimilars for psoriasis: clinical studies to determine similarity","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025042813573044400_ljae402-B5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"2025042813573044400_ljae402-B6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14712591003724670","article-title":"The use of ustekinumab in autoimmune disease","volume":"10","author":"Ryan","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"2025042813573044400_ljae402-B7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"2025042813573044400_ljae402-B8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40268-023-00441-7","article-title":"Analytical and functional similarity of the biosimilar candidate ABP 654 to ustekinumab reference product","volume":"23","author":"Cantin","year":"2023","journal-title":"Drugs R D"},{"key":"2025042813573044400_ljae402-B9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cpdd.1301","article-title":"Pharmacokinetic similarity of ABP 654, an ustekinumab biosimilar candidate: results from a randomized, double-blind study in healthy subjects","volume":"12","author":"Chow","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025042813573044400_ljae402-B10","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"2025042813573044400_ljae402-B11","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"2025042813573044400_ljae402-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/17474124.2015.1091307","article-title":"The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?","volume":"9","author":"Ben-Horin","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025042813573044400_ljae402-B13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"key":"2025042813573044400_ljae402-B14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nbt.1651","article-title":"Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins","volume":"28","author":"Ghaderi","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2025042813573044400_ljae402-B15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2019.00279","article-title":"Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities?","volume":"10","author":"Baumgart","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025042813573044400_ljae402-B16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","article-title":"The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases","volume":"80","author":"Kim","year":"2020","journal-title":"Drugs"},{"key":"2025042813573044400_ljae402-B17","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.21037\/tlcr-20-601","article-title":"A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation","volume":"9","author":"Garcia","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025042813573044400_ljae402-B18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/biom9090410","article-title":"The breakthrough of biosimilars: a twist in the narrative of biological therapy","volume":"9","author":"Kabir","year":"2019","journal-title":"Biomolecules"},{"key":"2025042813573044400_ljae402-B19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","article-title":"Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community","volume":"31","author":"Markus","year":"2017","journal-title":"BioDrugs"},{"key":"2025042813573044400_ljae402-B20","author":"U.S. Food and Drug Administration"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae402\/60011521\/ljae402.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/826\/60011521\/ljae402.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/826\/60011521\/ljae402.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:57:42Z","timestamp":1745848662000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/5\/826\/7833479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae402","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,10,23]]}}}